Philippe Moreau

107.7k total citations · 12 hit papers
1.0k papers, 32.4k citations indexed

About

Philippe Moreau is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Philippe Moreau has authored 1.0k papers receiving a total of 32.4k indexed citations (citations by other indexed papers that have themselves been cited), including 757 papers in Hematology, 452 papers in Oncology and 449 papers in Molecular Biology. Recurrent topics in Philippe Moreau's work include Multiple Myeloma Research and Treatments (677 papers), Protein Degradation and Inhibitors (273 papers) and Peptidase Inhibition and Analysis (170 papers). Philippe Moreau is often cited by papers focused on Multiple Myeloma Research and Treatments (677 papers), Protein Degradation and Inhibitors (273 papers) and Peptidase Inhibition and Analysis (170 papers). Philippe Moreau collaborates with scholars based in France, United States and Spain. Philippe Moreau's co-authors include Jean‐Luc Harousseau, Thierry Façon, Hervé Avet‐Loiseau, Michel Attal, Jesús F. San Miguel, Régis Bataille, Meletios Α. Dimopoulos, Cyrille Touzeau, Paul G. Richardson and Xavier Leleu and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Nature Communications.

In The Last Decade

Philippe Moreau

953 papers receiving 31.7k citations

Hit Papers

Definition of organ invol... 2005 2026 2012 2019 2005 2011 2017 2021 2017 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis
    2005 992 citations Philippe Moreau et al. profile →
  2. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study
    2011 661 citations Philippe Moreau, Xavier Leleu et al. profile →
  3. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    2017 518 citations Philippe Moreau, Jesús F. San Miguel et al. profile →
  4. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
    2021 460 citations Meletios Α. Dimopoulos, Philippe Moreau et al. profile →
  5. Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis
    2017 392 citations Cyrille Hulin, Pellegrino Musto et al. Journal of Clinical Oncology profile →
  6. Chemotherapy‐driven dysbiosis in the intestinal microbiome
    2015 365 citations Thomas Gastinne, Philippe Moreau et al. profile →
  7. Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma
    2018 364 citations Meletios Α. Dimopoulos, Philippe Moreau et al. profile →
  8. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial
    2020 256 citations Michèle Cavo, Kenshi Suzuki et al. profile →
  9. Anti–B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma
    2020 233 citations Michel Attal, Philippe Moreau et al. Journal of Clinical Oncology profile →
  10. Extramedullary disease in multiple myeloma: a systematic literature review
    2022 111 citations Joan Bladé, Philippe Moreau et al. profile →
  11. Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel
    2023 77 citations Noopur Raje, Sagar Lonial et al. profile →
  12. GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review
    2024 51 citations Philippe Moreau et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Philippe Moreau 19.7k 17.9k 14.4k 4.4k 3.7k 1.0k 32.4k
Shaji Kumar 23.4k 1.2× 22.8k 1.3× 14.0k 1.0× 5.7k 1.3× 2.5k 0.7× 1.0k 35.0k
Nikhil C. Munshi 21.5k 1.1× 25.2k 1.4× 16.7k 1.2× 3.6k 0.8× 3.4k 0.9× 799 40.1k
Bart Barlogie 30.7k 1.6× 24.5k 1.4× 18.3k 1.3× 5.7k 1.3× 3.4k 0.9× 704 42.4k
Philip R. Greipp 18.0k 0.9× 17.5k 1.0× 10.9k 0.8× 5.9k 1.4× 2.7k 0.7× 323 28.4k
Pieter Sonneveld 17.8k 0.9× 13.9k 0.8× 14.2k 1.0× 4.0k 0.9× 3.8k 1.0× 653 27.7k
Angela Dispenzieri 25.5k 1.3× 31.7k 1.8× 15.6k 1.1× 9.3k 2.1× 3.6k 1.0× 976 47.8k
Morie A. Gertz 20.6k 1.0× 30.3k 1.7× 13.6k 0.9× 9.9k 2.3× 3.7k 1.0× 945 44.0k
Martha Q. Lacy 15.8k 0.8× 16.8k 0.9× 9.4k 0.6× 5.2k 1.2× 2.0k 0.5× 554 25.4k
Stephen J. Forman 12.3k 0.6× 8.1k 0.5× 16.3k 1.1× 4.5k 1.0× 4.0k 1.1× 861 36.2k
Frederick R. Appelbaum 30.9k 1.6× 9.8k 0.5× 10.1k 0.7× 8.9k 2.0× 4.3k 1.2× 595 42.6k

Countries citing papers authored by Philippe Moreau

Since Specialization
Citations

This map shows the geographic impact of Philippe Moreau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philippe Moreau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philippe Moreau more than expected).

Fields of papers citing papers by Philippe Moreau

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philippe Moreau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philippe Moreau. The network helps show where Philippe Moreau may publish in the future.

Co-authorship network of co-authors of Philippe Moreau

This figure shows the co-authorship network connecting the top 25 collaborators of Philippe Moreau. A scholar is included among the top collaborators of Philippe Moreau based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philippe Moreau. Philippe Moreau is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Kraeber‐Bodéré, Françoise, et al.. (2023). New Developments in Myeloma Treatment and Response Assessment. Journal of Nuclear Medicine. 64(9). 1331–1343. 9 indexed citations
3.
Martin, Thomas G., Marcelo Capra, Mohamad Mohty, et al.. (2021). Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Patients Who Previously Underwent Transplantation: Ikema Subgroup Analysis. Transplantation and Cellular Therapy. 27(3). S65–S65. 2 indexed citations
4.
Raje, Noopur, David S. Siegel, Sundar Jagannath, et al.. (2021). Idecabtagene Vicleucel (ide-cel, bb2121) in Relapsed and Refractory Multiple Myeloma (RRMM): Analyses of High-Risk Subgroups in the KarMMa Study. Transplantation and Cellular Therapy. 27(3). S66–S67. 2 indexed citations
5.
Vij, Ravi, Rajneesh Nath, Daniel Afar, et al.. (2020). First-in-Human Phase I Study of ABBV-838, an Antibody–Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma. Clinical Cancer Research. 26(10). 2308–2317. 24 indexed citations
6.
Martin, Thomas G., Joseph Mıkhael, Roman Hájek, et al.. (2020). Depth of Response and Response Kinetics of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Ikema Interim Analysis. Blood. 136(Supplement 1). 7–8. 12 indexed citations
7.
Bailly, Clément, Thomas Carlier, Bastien Jamet, et al.. (2018). Interim PET Analysis in First-Line Therapy of Multiple Myeloma: Prognostic Value of ΔSUVmax in the FDG-Avid Patients of the IMAJEM Study. Clinical Cancer Research. 24(21). 5219–5224. 20 indexed citations
8.
9.
Magrangeas, Florence, Rowan Kuiper, Hervé Avet‐Loiseau, et al.. (2016). A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma. Clinical Cancer Research. 22(17). 4350–4355. 30 indexed citations
10.
11.
Surget, Sylvanie, David Chiron, Patricia Gomez‐Bougie, et al.. (2012). Cell Death via DR5, but not DR4, Is Regulated by p53 in Myeloma Cells. Cancer Research. 72(17). 4562–4573. 58 indexed citations
12.
Corre, Jill, Nicolas Espagnolle, Benjamin Hébraud, et al.. (2012). Bioactivity and Prognostic Significance of Growth Differentiation Factor GDF15 Secreted by Bone Marrow Mesenchymal Stem Cells in Multiple Myeloma. Cancer Research. 72(6). 1395–1406. 76 indexed citations
13.
Touzeau, Cyrille, Christelle Dousset, Patricia Gomez‐Bougie, et al.. (2011). ABT-737 Induces Apoptosis in Mantle Cell Lymphoma Cells with a Bcl-2 high /Mcl-1 low Profile and Synergizes with Other Antineoplastic Agents. Clinical Cancer Research. 17(18). 5973–5981. 49 indexed citations
14.
Fayers, Peter, Antonio Palumbo, Cyrille Hulin, et al.. (2011). Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood. 118(5). 1239–1247. 179 indexed citations
15.
Avet‐Loiseau, Hervé, Florent Malard, L. Campion, et al.. (2010). Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?. Blood. 117(6). 2009–2011. 92 indexed citations
16.
17.
Avet‐Loiseau, Hervé, Xavier Leleu, Murielle Roussel, et al.. (2010). Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p). Journal of Clinical Oncology. 28(30). 4630–4634. 298 indexed citations
18.
Moreau, Philippe, Arnaud Jaccard, Lotfi Benboubker, et al.. (2010). Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study. Blood. 116(23). 4777–4782. 96 indexed citations
19.
Hulin, Cyrille, Thierry Façon, Philippe Rodon, et al.. (2009). Efficacy of Melphalan and Prednisone Plus Thalidomide in Patients Older Than 75 Years With Newly Diagnosed Multiple Myeloma: IFM 01/01 Trial. Journal of Clinical Oncology. 27(22). 3664–3670. 266 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shaji Kumar Breakdown of academic impact, for papers by Nikhil C. Munshi Breakdown of academic impact, for papers by Bart Barlogie Breakdown of academic impact, for papers by Philip R. Greipp Breakdown of academic impact, for papers by Pieter Sonneveld Breakdown of academic impact, for papers by Angela Dispenzieri Breakdown of academic impact, for papers by Morie A. Gertz Breakdown of academic impact, for papers by Martha Q. Lacy Breakdown of academic impact, for papers by Stephen J. Forman Breakdown of academic impact, for papers by Frederick R. Appelbaum
Rankless by CCL
2026